<SEC-DOCUMENT>0001632295-25-000005.txt : 20251215
<SEC-HEADER>0001632295-25-000005.hdr.sgml : 20251215
<ACCEPTANCE-DATETIME>20251215161511
ACCESSION NUMBER:		0001632295-25-000005
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20251212
FILED AS OF DATE:		20251215
DATE AS OF CHANGE:		20251215

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Little Elisabeth Sandoval
		CENTRAL INDEX KEY:			0001632295
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38356
		FILM NUMBER:		251571765

	MAIL ADDRESS:	
		STREET 1:		C/O KYTHERA BIOPHARMACEUTICALS, INC.
		STREET 2:		30930 RUSSELL RANCH ROAD, 3RD FLOOR
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91362

	FORMER NAME:	
		FORMER CONFORMED NAME:	Sandoval Elisabeth
		DATE OF NAME CHANGE:	20150130

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VYNE Therapeutics Inc.
		CENTRAL INDEX KEY:			0001566044
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				453757789
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		685 ROUTE 202/206 N., SUITE 301
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		800-775-7936

	MAIL ADDRESS:	
		STREET 1:		685 ROUTE 202/206 N., SUITE 301
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics Inc.
		DATE OF NAME CHANGE:	20180201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170728

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tigercat Pharma, Inc.
		DATE OF NAME CHANGE:	20130104
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4-12152025_041207.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-12-12</periodOfReport>

    <issuer>
        <issuerCik>0001566044</issuerCik>
        <issuerName>VYNE Therapeutics Inc.</issuerName>
        <issuerTradingSymbol>VYNE</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001632295</rptOwnerCik>
            <rptOwnerName>Little Elisabeth Sandoval</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O VYNE THERAPEUTICS INC.</rptOwnerStreet1>
            <rptOwnerStreet2>P.O. BOX 125</rptOwnerStreet2>
            <rptOwnerCity>STEWARTSVILLE</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08886</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.3756</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-12-12</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>20000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-12-11</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>20000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>20000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Mutya Harsch, Attorney-in-Fact</signatureName>
        <signatureDate>2025-12-15</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
